Zynext Ventures Invests in Feldan Therapeutics to Advance Next-Gen Intracellular Drug Delivery

Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Feldan Therapeutics...

April 17, 2025 | Thursday | News
Nikon CeLL and RoosterBio Ink Licensing Deal to Advance Stem Cell and EV Therapies in Japan

Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc. (RoosterBi...

April 16, 2025 | Wednesday | News
Lecanemab Becomes First Approved Disease-Modifying Therapy for Early Alzheimer’s in the EU

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild de...

April 16, 2025 | Wednesday | News
Regeneron and Sanofi Receive Approval for Dupixent® in Japan to Treat Chronic Obstructive Pulmonary Disease (COPD)

TARRYTOWN -- Regeneron Pharmaceuticals, and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...

March 31, 2025 | Monday | News
Rhythm Pharmaceuticals Receives Orphan Drug Designation for Setmelanotide in Japan for Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendoc...

March 21, 2025 | Friday | News
Ionis and Ono Pharmaceutical Partner on Sapablursen for Polycythemia Vera with Exclusive Global Rights Agreement

 Ionis Pharmaceuticals, Inc. and Ono Pharmaceutical Co., Ltd (Ono), announced that the two companies have entered into a license agreement in whi...

March 12, 2025 | Wednesday | News
Nxera Pharma Signs Agreement with Viatris and Idorsia for Cenerimod Development and Commercialization in Japan, South Korea, and APAC

Nxera Pharma has entered an assignment agreement with Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Pharmaceuticals Ltd (&...

February 28, 2025 | Friday | News
Polycythemia Vera A Rare Blood Disorder Affecting Thousands

Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an accompanying increase in white bloo...

February 27, 2025 | Thursday | News
Biogen and Stoke Therapeutics Collaborate on Zorevunersen for Dravet Syndrome Treatment

Biogen Inc.  and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...

February 19, 2025 | Wednesday | News
Regeneron’s EYLEA HD® 8 mg Shows Promise for Retinal Vein Occlusion in Phase 3 QUASAR Trial

Regeneron Pharmaceuticals, Inc.announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (afliber...

February 10, 2025 | Monday | News
Revive Therapeutics Focuses on Bucillamine for Medical Countermeasures and Nerve Agent Exposure Treatment

 Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences com...

February 04, 2025 | Tuesday | News
Eisai and Biogen Provide Update on Lecanemab’s EU Regulatory Review for Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

February 04, 2025 | Tuesday | News
China’s NMPA Approves Sarclisa for Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomid...

February 03, 2025 | Monday | News
GHIT Fund Announces JPY 2 Billion Investment in New Diagnostics and Drugs for Neglected Tropical Diseases and Malaria

The Global Health Innovative Technology (GHIT) Fund announced a total investment of approximately JPY 2 billion (USD 12.7 million1) in eight...

January 30, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close